NASDAQ:EPRX Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis $7.40 +0.30 (+4.23%) As of 01:44 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get EPRX alerts:Sign Up Key Stats Today's Range$7.17▼$7.5250-Day Range$6.29▼$7.8052-Week Range$3.82▼$9.32Volume159,158 shsAverage Volume216,066 shsMarket Capitalization$447.18 millionP/E RatioN/ADividend YieldN/APrice Target$18.33Consensus RatingModerate Buy Company Overview Eupraxia Pharmaceuticals, Inc. (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus. Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline. The company has established preclinical programs targeting additional autoimmune indications and is preparing to initiate subsequent trials as it builds clinical proof-of-concept for its Treg-focused approach. Eupraxia’s management team comprises seasoned professionals with expertise in immunology, drug development and regulatory affairs. The leadership is committed to leveraging decades of collective experience in biopharma to guide the company’s progression from early-stage research toward potential regulatory milestones and commercial readiness. As a publicly traded company on NASDAQ, Eupraxia Pharmaceuticals aims to deliver innovative, first-in-class treatments that address unmet medical needs in chronic immune-mediated conditions.AI Generated. May Contain Errors. Read More Eupraxia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreEPRX MarketRank™: Eupraxia Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 599th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEupraxia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEupraxia Pharmaceuticals has a consensus price target of $18.33, representing about 147.7% upside from its current price of $7.40.Amount of Analyst CoverageEupraxia Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eupraxia Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Eupraxia Pharmaceuticals are expected to decrease in the coming year, from ($0.86) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eupraxia Pharmaceuticals is -7.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eupraxia Pharmaceuticals is -7.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEupraxia Pharmaceuticals has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eupraxia Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.09% of the float of Eupraxia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 17.77, which indicates bearish sentiment.Change versus previous monthShort interest in Eupraxia Pharmaceuticals has recently increased by 19.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEupraxia Pharmaceuticals does not currently pay a dividend.Dividend GrowthEupraxia Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.61 News SentimentEupraxia Pharmaceuticals has a news sentiment score of -0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eupraxia Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Eupraxia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsEupraxia Pharmaceuticals has minimal institutional ownership at this time.Read more about Eupraxia Pharmaceuticals' insider trading history. Receive EPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPRX Stock News HeadlinesStifel initiates coverage of Eupraxia Pharmaceuticals (EPRX) with buy recommendationMay 22, 2026 | msn.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMay 20, 2026 | americanbankingnews.comThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing confirmed. Goldman, Morgan Stanley, and 19 other banks have already carved up the allocation. But buried in those 277 pages is a detail most investors will miss. One small, publicly traded company is so critical to SpaceX's infrastructure that Musk can't scale without it - and the S-1 just confirmed it.May 26 at 1:00 AM | Behind the Markets (Ad)Cartesian Therapeutics (NASDAQ:RNAC) & Eupraxia Pharmaceuticals (NASDAQ:EPRX) Critical ContrastMay 19, 2026 | americanbankingnews.comHC Wainwright Issues Pessimistic Outlook for EPRX EarningsMay 18, 2026 | americanbankingnews.comWall Street Zen Downgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to Strong SellMay 16, 2026 | americanbankingnews.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 13, 2026 | finanznachrichten.deEupraxia Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 12, 2026 | financialpost.comFSee More Headlines EPRX Stock Analysis - Frequently Asked Questions How have EPRX shares performed this year? Eupraxia Pharmaceuticals' stock was trading at $7.55 at the start of the year. Since then, EPRX stock has decreased by 2.0% and is now trading at $7.40. How were Eupraxia Pharmaceuticals' earnings last quarter? Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.01. Who are Eupraxia Pharmaceuticals' major shareholders? Top institutional investors of Eupraxia Pharmaceuticals include Affinity Asset Advisors LLC (2.63%), Redmile Group LLC (1.16%), Rubric Capital Management LP (1.14%) and Ally Bridge Group NY LLC (1.09%). How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eupraxia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Cos (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY). Company Calendar Last Earnings5/12/2026Today5/26/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 5 days ago, EPRX's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EPRX Previous SymbolNASDAQ:EPRX CIK1581178 Webwww.eupraxiapharma.com Phone250-590-3968FaxN/AEmployees29Year Founded2012Price Target and Rating Average Price Target for Eupraxia Pharmaceuticals$18.33 High Price Target$25.00 Low Price Target$11.00 Potential Upside/Downside+147.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.56% Return on Assets-51.20% Debt Debt-to-Equity Ratio0.02 Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book4.20Miscellaneous Outstanding Shares60,430,000Free FloatN/AMarket Cap$447.18 million OptionableN/A Beta1.19 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:EPRX) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredYour computer is about to become a museum pieceFor 67 years, chip-making meant slicing a single silicon wafer into hundreds of pieces. Three companies just a...Eagle Publishing | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNew Warning From Our CEOMarketWise CEO Dr. David 'Doc' Eifrig, a former Goldman Sachs derivatives trader, has released an urgent brief...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
